Welcome to the sixth
issue of the Neuronet newsletter!
|
|
We hope this newsletter finds you well. This sixth newsletter issue provides you with up-to-date insights on the Innovative Medicines Initiative’s (IMI) research efforts to tackle challenges in neurodegeneration.
Although COVID-19 has had world-wide implications on research, it is very impressive to see how well projects keep on progressing. On that matter, we were very happy to launch the Neuronet Knowledge Base at the beginning of February, providing you with a comprehensive overview of the fantastic outputs the projects have been generating.
Apart from providing you with project updates, we also interviewed Clint Hansen from the Mobilise-D consortium as part of our spotlight on early-career investigators.
At the bottom of this newsletter you will find a link to the videos of our event on working together to address common challenges for European neurodegeneration research, that was recorded as part of the Alzheimer Europe conference. Do check them out and make sure to subscribe to our YouTube channel.
Happy reading and stay safe!
|
|
|
Carlos Díaz
Neuronet Project Coordinator
CEO, SYNAPSE
Research Management Partners
|
|
Lennert Steukers
Neuronet Project Leader
Associate Director,
Clinical Scientist, Janssen Pharmaceutica NV
|
|
Interviews ___________________________________________________________________
|
Spotlight on early-career investigators: a Neuronet interview with Clint Hansen
|
|
|
We spoke to Clint Hansen who is working towards the technical validation of a sensor algorithm that will enable accurate assessment of the mobility of participants in the Mobilise-D clinical study.
|
|
News ___________________________________________________________________
|
Neuronet launches Knowledge Base
|
|
|
The Knowledge Base brings together key information about the various projects of the IMI ND portfolio. This comprehensive resource is an integral part of our endeavour to boost collaboration across the research portfolio by assisting in identifying gaps, multiplying the portfolio’s impact, and enhancing its visibility with related initiatives in Europe and worldwide.
|
|
IDEA-FAST project progress update
|
|
|
Although COVID-19 restrictions had their implications, Consortium members have been busy adapting to the new situation and developing alternative plans. Here we provide you with a high-level overview of their recent activities and achievements.
|
|
European Medicines Agency supports Mobilise-D to pursue the qualification of Digital Mobility Outcomes as biomarkers
|
|
|
In 2019, the Mobilise-D consortium requested qualification advice for Digital Mobility Outcomes (DMOs) at the European Medicines Agency. This initial qualification is part of the Mobilise-D’s wider objective to establish acceptable DMOs (derived from suitable mobile wearable devices and associated algorithms) as biomarkers for clinical benefit (i.e., as surrogate, primary or key secondary endpoints) in pivotal clinical trials for treatment of diseases or health conditions that impact upon mobility.
|
|
IDEA-FAST and Mobilise-D join forces to strengthen research and development of digital biomarkers
|
|
|
From January 2021 onwards, two EU Innovative Medicines Initiatives, IDEA-FAST and Mobilise-D, will join forces to increase the impact and the benefits of digital health technologies developed by both projects.
|
|
The final EPAD dataset is now available to the entire research community
|
|
|
The European Prevention of Alzheimer’s Dementia (EPAD) project is very pleased to announce the external release of its final dataset for all researchers from over the world. The final dataset is called Version.IMI (V.IMI) as it represents all the data collected and processed during the IMI period of EPAD.
|
|
AMYPAD project announces end of recruitment in the Diagnostic and Patient Management Study
|
|
|
At the end of 2020, the members of the AMYPAD project announced the completion of the enrolment of research participants in its Diagnostic and Patient Management Study. In this randomised clinical study, participants with possible Alzheimer’s disease were included to determine the usefulness of β-amyloid imaging as a diagnostic marker for dementia.
|
|
RCSI STEM careers promotion talks present
PD-MitoQUANT to young people
|
|
|
Midlands Science partnered with Helena Bonner, a Neuroscientist at the Royal College of Surgeons in Ireland, as well as an Outreach officer at the Centre for Systems Medicine, RCSI to provide informative virtual talks for a number of schools across the Midlands for College Awareness Week.
|
|
RADAR-CNS Epilepsy Study 2 begins recruitment
|
|
|
The RADAR-CNS Epilepsy Study team based at King’s College London recruited their first participants to Study 2. The Study 2 participants are asked to wear a wrist-worn device to measure various parameters including movement and heart rate. Their stress, mood and sleep will also be monitored with some active apps downloaded on mobile devices.
|
|
AETIONOMY & EPAD researchers launch AData(Viewer) an online tool to explore the Dataset Landscape in Alzheimer's Disease
|
|
|
To assess the Alzheimer's disease data landscape, Colin Birkenbihl and colleagues analysed datasets from 9 cohort studies, including the EMIF-1000 and EPADv1500 studies. Summarising the data parameters and describing how they overlap between studies, they observed fairly large biases towards high levels of education and, in particular, a strong bias towards white/Caucasian ethnicity. All the analyses reported in the article have been made available through “ADataViewer”, an interactive web application developed by Fraunhofer SCAI that displays the findings in data availability maps.
|
|
Event ___________________________________________________________________
|
Presentations from annual Neuronet event at the Alzheimer Europe conference are now online
|
|
|
This year, we expanded the focus of the event, titled "Working together to address common challenges for European neurodegeneration research". Over the course of four parallel sessions, we showcased the work of IMI neurodegeneration projects on data sharing, ethics and regulatory/HTA interactions, and hosted presentations from early-career investigators working on these projects. In addition, we held a roundtable discussion, during which project leaders discussed the challenges experienced by public-private partnerships during the COVID-19 pandemic, and how research will evolve in the critical post-COVID period.
|
|
Neuronet project newsletters ___________________________________________________________________
|
|
|
What we are reading ___________________________________________________________________
|
Funding ___________________________________________________________________
|
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.
Any related content solely reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
|
|
|
|
|